MelanomArray

The discovery of a mutation in the BRAF gene is an indication for the administration of targeted therapy (BRAF inhibitors).

Similarly, in the event that no mutation is found in the BRAF gene, the discovery of a mutation in the KIT gene is an indication for the administration of targeted therapy (KIT inhibitors).

The discovery of a mutation in the NRAS gene is an indication for the administration of targeted therapy (MEK inhibitors).
The detection of translocations in the NTRK1, NTRK2, NTRK3, ALK, ROS1 genes is an indication of response to targeted therapy with the corresponding inhibitors (e.g. TRK inhibitors).

The tests are performed on the surgical specimen (paraffin cubes) or the biopsy material (paraffin cube) from which your histological examination was performed or on the aspiration material (FNAB, EBUS) from which your cytological examination was performed. In our fully integrated Laboratory, the pathologist selects the most appropriate & representative paraffin cube, ensuring that the most appropriate sample will be used for the tests. Qualitative and quantitative parameters are checked.

In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.

In our fully integrated Laboratory, we handle your sample in such a way as to minimize its unnecessary waste:

• The paraffin cube is placed, if possible, once on the microtome for obtaining tissue sections, by experienced tissue technologists.
• Tissue sections are obtained sequentially in such a way as to ensure diagnosis and perform Immunohistochemistry if required.
• Ensuring preservation of tissue sections for further molecular testing.
• Pathologists perform microdissection to ensure the maximum amount of cancer cells possible, removing all other necrotic cells or normal tissue that could affect the validity of the results.
• The molecular biologist immediately processes the tissue in a fully controlled environment, using next-generation sequencing (NGS) or real-time polymerase chain reaction (Real-time PCR) to identify mutations in the genes of interest.

The discovery of a mutation in the BRAF gene is an indication for the administration of targeted therapy (BRAF inhibitors).

Similarly, in the event that no mutation is found in the BRAF gene, the discovery of a mutation in the KIT gene is an indication for the administration of targeted therapy (KIT inhibitors).

The discovery of a mutation in the NRAS gene is an indication for the administration of targeted therapy (MEK inhibitors).
The detection of translocations in the NTRK1, NTRK2, NTRK3, ALK, ROS1 genes is an indication of response to targeted therapy with the corresponding inhibitors (e.g. TRK inhibitors).

The tests are performed on the surgical specimen (paraffin cubes) or the biopsy material (paraffin cube) from which your histological examination was performed or on the aspiration material (FNAB, EBUS) from which your cytological examination was performed. In our fully integrated Laboratory, the pathologist selects the most appropriate & representative paraffin cube, ensuring that the most appropriate sample will be used for the tests. Qualitative and quantitative parameters are checked.

In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.

Most of the time, the sample material we are called upon to handle is small because it has resulted from a minimally invasive method (needle biopsy, fluid aspiration, paraffin block with minimal material).

In our laboratory, Pathologists check in a timely manner whether the material to be examined is sufficient. If so, then a management algorithm is followed, with the aim of achieving the performance of multiple tests on the material (Immunohistochemistry, real-time PCR, NGS) in order to fully check the molecular profile of your tumor (proteins, genes, histological Grading).

In this case, and once sample enrichment manipulations have been exhausted, we contact your clinician to discuss alternative approaches in order to obtain the desired information to select the optimal treatment for you. Some examples:

• Performing an alternative test (e.g. Immunohistochemistry instead of PCR, or choosing Next Generation Sequencing (NGS))
• Performing Immunohistochemistry instead of FISH (Fluorescent In Situ Hybridization) and tubulin
• Possible blood sampling instead of tissue testing (liquid biopsy)
• Possible option to take a new biopsy or puncture

In case your sample is not already at Microdiagnostics archive, please contact us immediately so that we can arrange for its safe and rapid transport to our laboratory. You will also need to quickly and easily complete the Consent Form.

By cash, bank card, bank deposit, or Online interbank deposit.

One of the primary concerns at Microdiagnostics is the protection of your personal data as well as the strict observance of the conditions for the protection of your genetic material and medical results.

In full compliance with the General Data Protection Regulation (GDPR), we ensure that any test conducted is done with your knowledge and consent and we do not communicate results over the phone.